These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 26628427

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PURLs: Need an add-on to metformin? Consider this.
    Wyncott D, Lyon C, Mounsey A.
    J Fam Pract; 2017 Jan; 66(1):42-44. PubMed ID: 28188318
    [Abstract] [Full Text] [Related]

  • 3. Incorporating New Medications in Diabetes Care.
    Comi RJ.
    Ann Intern Med; 2015 Nov 03; 163(9):719-20. PubMed ID: 26458033
    [No Abstract] [Full Text] [Related]

  • 4. Which oral agent to use when metformin is no longer effective?
    Bannon M.
    QJM; 2011 Mar 03; 104(3):183-4. PubMed ID: 21330402
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE.
    Endocrinol Metab Clin North Am; 2007 Dec 03; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract] [Full Text] [Related]

  • 7. Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
    Christensen M, Knop FK.
    Nat Rev Endocrinol; 2012 Oct 03; 8(10):576-8. PubMed ID: 22926098
    [No Abstract] [Full Text] [Related]

  • 8. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun 03; 18(101):115. PubMed ID: 19637427
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacologic Agents Used to Treat Type 2 Diabetes.
    Moran KJ, Burson R.
    Home Healthc Now; 2017 Jun 03; 35(7):394-395. PubMed ID: 28650371
    [No Abstract] [Full Text] [Related]

  • 13. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B.
    FP Essent; 2017 May 03; 456():27-35. PubMed ID: 28530382
    [Abstract] [Full Text] [Related]

  • 14. Diabetes under control: Understanding oral antidiabetic agents.
    Longo R.
    Am J Nurs; 2010 Feb 03; 110(2):49-52. PubMed ID: 20107402
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S, Saxena GN, Keshwani P, Gupta R.
    J Assoc Physicians India; 2012 Mar 03; 60():27-30. PubMed ID: 22799111
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A.
    Diabetes Metab Res Rev; 2012 Dec 03; 28 Suppl 2():21-5. PubMed ID: 23280862
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. (7) Approaches to glycemic treatment.
    American Diabetes Association.
    Diabetes Care; 2015 Jan 03; 38 Suppl():S41-8. PubMed ID: 25537707
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.